NasdaqCM - Nasdaq Real Time Price USD

Veru Inc. (VERU)

2.1500 -0.0100 (-0.46%)

As of 1:08:01 PM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

GlobeNewswire 2mo ago

VERU
-0.46%
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

GlobeNewswire 3mo ago

VERU
-0.46%
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

GlobeNewswire 3mo ago

VERU
-0.46%
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

GlobeNewswire 3mo ago

VERU
-0.46%
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

GlobeNewswire 5mo ago

VERU
-0.46%
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

GlobeNewswire 1mo ago

VERU
-0.46%
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

GlobeNewswire 2mo ago

VERU
-0.46%
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

GlobeNewswire 2mo ago

VERU
-0.46%
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

GlobeNewswire 2mo ago

VERU
-0.46%
Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty

PR Newswire 3mo ago

6576.TWO

STX.L

VERU
-0.46%
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

GlobeNewswire 7mo ago

VERU
-0.46%
Veru to Report Fiscal Year 2025 Financial Results on December 17th

GlobeNewswire 10mo ago

VERU
-0.46%

Performance Overview

Return	VERU	S&P 500 (^GSPC)
YTD	--	+10.74%
1-Year	-17.69%	+10.63%
3-Year	-78.60%	+73.93%

U.S. markets close in 2h 47m

Veru Inc. (VERU)

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru to Report Fiscal Year 2025 Financial Results on December 17th